A global phase 3 clinical study of Brincidofovir IV for pediatric patients with adenovirus (AdV) infections occurring after hematopoietic stem cell transplantation

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 01 Mar 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

23 Jan 2023 According to a SymBio Pharmaceuticals media release, if the phase 2 trial progresses smoothly, the company could start talks with the FDA in he second half of 2023 and start this trial in 2024.
11 Aug 2020 New trial record
05 Aug 2020 According to a SymBio Pharmaceuticals media release, the company's Board of Directors today approved a global clinical development plan for antiviral drug brincidofovir (BCV) intravenous formulation. Development will primarily be focused in Japan, the U.S., and the EU. The company will proceed with a global clinical study for pediatric patients with adenovirus (AdV) infections occurring after hematopoietic stem cell transplantation.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com